Dot1L-IN-5 产品活性：Dot1L-IN-5 是一种有效的类端粒沉默干扰体 1 (DOT1L) 抑制剂，IC50 为 0.17 nM。 产品来源： https://www.medchemexpress.cn/dot1l-in-5.html 研究领域：Epigenetics 作用靶点：Histone Methyltransferase In Vitro: Dot1L-IN-5 (Compound 11) is tested in cellular assays to assess the ability to inhibit the dimethylation of H3K79 in HeLa cells (ED50 H3K79me2 Elisa=2.9 nM) and HOXA9 gene expression in Molm-13 cells (ED50 HOXA9 RGA=30 nM). In Vivo: Dot1L-IN-5 (Compound 11; subcutaneous injection; at 75 mg/kg once daily for 20 days) does not lead to tumor growth inhibition in NOD-SCID mice. Dot1L-IN-5 (subcutaneous injection; at 75 mg/kg twice daily for 20 days) leads 73% growth inhibition. While both treatment regimens result in very strong inhibition of global H3K79 dimethylation level in tumor, the efficacious regimen is superior in reducing the mRNA expression of the target genes HOXA9 and MEIS1. 相关产品：Bioactive Compound Library Plus | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Reprogramming Compound Library | Anti-Blood Cancer Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Highly Selective Inhibitors Library | Anti-Hematopathy Compound Library | Bioactive Compound Library Max | GSK126 | Pinometostat | Tazemetostat | GSK3326595 | 3-Deazaneplanocin A hydrochloride | GSK343 | GSK3368715 dihydrochloride | BIX-01294 | EPZ015666 | EZM0414 TFA | Chaetocin | EED226 | MS023 | UNC1999 | Onametostat | OICR-9429 | EZM 2302 | MRTX-1719 | UNC0642 | UNC0379 | SGC0946 | UNC0224 | GSK591 | Sinefungin | EPZ004777 | MS177 | UNC0638 | A-366 | TP-064 | NSC 663284 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。